Low Intensity Shockwave Therapy for Erectile Dysfunction

Low-intensity shockwave therapy (LiSWT) has been deemed "a safe and well-tolerated procedure but its efficacy for the treatment of ED is doubtful and deserves more investigation" by the European Society of Sexual Medicine. In a similar manner, the Sexual Medicine Society of North America and American Urological Association have put forth guideline statements recommending additional investigation of this treatment modality.2

The current clinical armamentarium only treats the symptoms of erectile dysfunction without improving upon the underlying pathophysiology. LiSWT has been used effectively in musculoskeletal disorders and cardiovascular applications. Animal studies have shown improvements in angiogenesis and stem cell recruitment in other systems (cardiac and musculoskeletal) using shockwave therapy. It has been used to treat erectile dysfunction since 2010 and is widely used in Europe and throughout the world. It is gaining widespread acceptance in the United States with a relative paucity of data in regards to its effectiveness.

While the majority of studies and meta-analyses show improvements in standardized erectile dysfunction questionnaires (IIEF/SHIM-Sexual Health Inventory in Men, International Index of Erectile Function-5) the durability remains unknown and many have lacked a sham-arm. In addition, many studies have failed to assess a population of men who have highly prevalent erectile dysfunction, those men undergoing prostate cancer treatment.

This is a prospective, randomized, single blind, sham-controlled clinical study aimed to evaluate the safety and efficacy of low-intensity shockwave therapy (LiSWT) on symptomatic ED patients in three distinct patient populations. LiSWT has shown the potential to improve baseline erectile function but requires further study, which is the aim of this investigation.

Study Overview

• Status: Active, not recruiting
• Conditions: Erectile Dysfunction; Erectile Dysfunction Following Radical Prostatectomy; Erectile Dysfunction Following Radiation Therapy; Erectile Dysfunction Due to General Medical Condition; Erectile Dysfunction Due to Arterial Insufficiency
• Intervention / Treatment: Device: Storz Duolith Low-Intensity Shockwave Therapy

Detailed Description

It is estimated that about 1 in 10 adult males suffer from erectile dysfunction (ED) on a long-term basis. Oral therapies, including PDE5I, may be considered first-line therapies for the majority of patients with ED because of potential benefits and lack of invasiveness. This is a prospective, randomized, single-blind, sham-controlled clinical study aimed to evaluate the safety and efficacy of low-intensity shockwave therapy on symptomatic ED patients in three distinct patient populations.

The first arm of the study will be those men with erectile dysfunction as defined by IIEF score (International Index of Erectile Function-5). These men will either have PDE5i refractory or responsive erectile dysfunction. Subjects will receive either Sham treatment (no ultrasound energy delivered via a Sham probe) or LiSWT for erectile dysfunction. Follow up will occur at 1 month, 3 months, and 6 months following the end of treatment. Effectiveness will be measured by change in IIEF/SHIM (IIEF/SHIM-Sexual Health Inventory in Men, International Index of Erectile Function-5) score and EHS (Erection Hardness Score) score.

The Sexual Health Inventory in Men (also referred to as International Index of Erectile Function-5) is scored as follows:

22-25 No erectile dysfunction 17-21 Mild erectile dysfunction 12-16 Mild-to-moderate erectile dysfunction 8-11 Moderate erectile dysfunction 5-7 Severe erectile dysfunction

The patient responds to the following questions:

Instructions Each question has 5 possible responses. Circle the number that best describes your own situation.

Select only 1 answer for each question.

Over the past 6 months:

1. How do you rate your confidence that you could keep an erection? Very low (1), Low (2), Moderate (3), High (4), Very high (5)

2. When you had erections with sexual stimulation, how often were your erections hard enough for penetration (entering your partner)?

   Almost never or never (1), A few times (much less than half the time) (2), Sometimes (About half the time) (3), Most times (much more than half the time) (4), Almost always or always (5)

3. During sexual intercourse, how often were you able to maintain your erection after you had penetrated (entered) your partner?

   Almost never or never (1), A few times (much less than half the time) (2), Sometimes (About half the time) (3), Most times (much more than half the time) (4), Almost always or always (5)

4. During sexual intercourse, how difficult was it to maintain your erection to completion of intercourse?

   Extremely difficult (1), Very difficult (2), Difficult (3), Slightly difficult (4), Not difficult (5)

5. When you attempted sexual intercourse, how often was it satisfactory for you? Almost never or never (1), A few times (much less than half the time) (2), Sometimes (About half the time) (3), Most times (much more than half the time) (4), Almost always or always (5)

An increase or decrease from baseline indicates improving or worsening erectile function. The Erection Hardness score is another tool to evaluate erectile function and firmness. It is scored as follows:

0-Penis does not enlarge

1. Penis is larger, but not hard
2. Penis is hard, but not hard enough for penetration
3. Penis is hard enough for penetration, but not completely hard
4. Penis is completely hard and fully rigid

These patients will be randomized in a 1:1 ratio into either the Sham or active treatment groups in which a device called Duolith by Storz will be used to deliver shockwaves to the penile tissue. The Duolith device is FDA-approved for treatment of musculoskeletal disorders including plantar fasciitis but has more recently been investigated in erectile dysfunction in both the United States and abroad.

The Duolith device is used to deliver low intensity shockwaves to the penile tissue. LiSWT (Linear Shockwave Therapy) utilizes energy in the ultrasonic range. The focused energy, when applied to tissue, has been postulated to improve stem cell recruitment and promote angiogenesis. This has been demonstrated in animal modes.

The second population of patients will be those who are planning to undergo treatment for prostate cancer. In a similar manner, men will be randomized to either the Sham or active treatment groups. Men will be treated prior to undergoing definitive treatment for prostate cancer to assess the effectiveness in LiSWT as a means of erectile preservation prior to prostate cancer treatment.

The third population of patients will be those who have undergone treatment for prostate cancer. The investigators will compare IIEF scores and EHS scores in men who have undergone prostatectomy or radiation therapy. Again, there will be a sham and treatment group.

In addition to assessing the efficacy of LiSWT in these populations of men, the study aims also to substantiate the safety profile of the Duolith device. Safety is to be assessed by the frequency of side effects during treatment, as well as the occurrence of anticipated and unanticipated adverse events during and from treatment up to follow-ups. The average and standard deviation of all relevant variables, including demographic and baseline characteristics, primary and secondary outcomes will be calculated.

• Study Type: Interventional
• Enrollment (Anticipated): 338
• Phase: Early Phase 1

Contacts and Locations

Study Locations

• United States
  • Virginia
    • Charlottesville, Virginia, United States, 22908
      • University of Virginia

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• The patient must be willing and able to provide informed consent.
• The patient is a male between >30 and <80 years of age.
• PDE5i responsive or non-responsive. If on PDE5i patient will discontinue medication for 2 weeks before baseline IIEF.
• Baseline IIEF-EF score ≥ 8 and ≤21. If taking PDE5i, stop medication for at least 4 weeks before baseline IIEF.
• Testosterone level > 300 ng/dL. This includes patients on therapeutic testosterone therapy.
• If diabetic, HgbA1C level ≤ 7.5% within 3 months prior to enrollment.
• Men who have undergone radical prostatectomy ≥ 12 months ago
• Men who have undergone radiation therapy, either brachytherapy or external bean therapy ≥ 12 months ago

Exclusion Criteria:

• History of extensive pelvic surgery ever.
• Past radiation therapy of the pelvic region within 12 months prior to enrollment.
• Recovering from any non-prostate related cancer within 12 months prior to enrollment.
• Neurological disease which affects erectile function at the discretion of the investigator.
• Anatomical malformation of the penis, including Peyronie's disease.
• Testosterone level <300 within 3 month prior to enrollment.
• HgbA1C level > 7.5% within 3 month prior to enrollment.
• History of spinal cord injury.
• Recovering from any non-prostate cancer malignancy within 12 months prior to enrollment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Baseline Erectile Dysfunction; The first arm of the study will be those men with erectile dysfunction as defined by IIEF score. These men will either have PDE5i refractory or responsive erectile dysfunction. Subjects will receive either Sham treatment (no ultrasound energy delivered via a Sham probe) or LiSWT for erectile dysfunction. Follow up will occur at 1 month, 3 months, and 6 months following the end of treatment. Effectiveness will be measured by change in IIEF/SHIM score and EHS score. Each questionnaire is described in the trial description with a higher score indicating improved function.	Device: Storz Duolith Low-Intensity Shockwave Therapy; A: Sham - the sham uses an attachment on the hand held probe that mimics the shockwave device, however it does not deliver any shockwaves. Sham will be delivered twice weekly for 3 weeks in the same manner as the LiSWT. The sham treatment will take about 20 minutes to complete. B: LiSWT delivered twice weekly for 3 weeks, comprising of 3000 shockwaves delivered to the distal penis (1000 shockwaves), base of penis (1000 shockwaves), and corporal bodies on the perineum (500 shockwaves to each crura). LiSWT is delivered into the penile tissue by a small hand held probe that produces low intensity shockwaves. A tranducer head is placed on the left and right sides of the penis. Treatment takes about 20 minutes to complete.; Other Names: Sham
Active Comparator: Erectile Dysfunction-Penile Rehabilitation; The second population of patients will be those who are planning to undergo treatment for prostate cancer. In a similar manner, men will be randomized to either the Sham or active treatment groups. Men will be treated prior to undergoing definitive treatment for prostate cancer to assess the effectiveness in LiSWT as a means of erectile preservation prior to prostate cancer treatment.	Device: Storz Duolith Low-Intensity Shockwave Therapy; A: Sham - the sham uses an attachment on the hand held probe that mimics the shockwave device, however it does not deliver any shockwaves. Sham will be delivered twice weekly for 3 weeks in the same manner as the LiSWT. The sham treatment will take about 20 minutes to complete. B: LiSWT delivered twice weekly for 3 weeks, comprising of 3000 shockwaves delivered to the distal penis (1000 shockwaves), base of penis (1000 shockwaves), and corporal bodies on the perineum (500 shockwaves to each crura). LiSWT is delivered into the penile tissue by a small hand held probe that produces low intensity shockwaves. A tranducer head is placed on the left and right sides of the penis. Treatment takes about 20 minutes to complete.; Other Names: Sham
Active Comparator: Erectile Dysfunction Post-Prostate Cancer Treatment; The third population of patients will be those who have undergone treatment for prostate cancer. The investigators will compare IIEF scores and EHS scores in men who have undergone prostatectomy or radiation therapy. Again, there will be a sham and treatment group.	Device: Storz Duolith Low-Intensity Shockwave Therapy; A: Sham - the sham uses an attachment on the hand held probe that mimics the shockwave device, however it does not deliver any shockwaves. Sham will be delivered twice weekly for 3 weeks in the same manner as the LiSWT. The sham treatment will take about 20 minutes to complete. B: LiSWT delivered twice weekly for 3 weeks, comprising of 3000 shockwaves delivered to the distal penis (1000 shockwaves), base of penis (1000 shockwaves), and corporal bodies on the perineum (500 shockwaves to each crura). LiSWT is delivered into the penile tissue by a small hand held probe that produces low intensity shockwaves. A tranducer head is placed on the left and right sides of the penis. Treatment takes about 20 minutes to complete.; Other Names: Sham

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in IIEF/SHIM score (International Index of Erectile-Function-5, Sexual Health Inventory in Men) Score at 1 month post-treatment	The primary outcome will be change in (International Index of Erectile-Function-5, Sexual Health Inventory in Men) score from baseline (pre-treatment) to 1 month after the end of treatment. The IIEF/SHIM score is a validated instrument to assess erectile function. Over the past 6 months: How do you rate your confidence that you could keep an erection?; When you had erections with sexual stimulation, how often were your erections hard enough for penetration (entering your partner)?; During sexual intercourse, how often were you able to maintain your erection after you had penetrated (entered) your partner?; During sexual intercourse, how difficult was it to maintain your erection to completion of intercourse?; When you attempted sexual intercourse, how often was it satisfactory for you? Each item is scored 1-5, with a higher number indicating better rigidity.	1 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in (International Index of Erectile-Function-5, Sexual Health Inventory in Men) at 3 and 6 months post-treatment	Changes in SHIM score (Sexual Health Inventory in Men) score at 3 and 6 months post-treatment. • The IIEF classifies men into groups of no erectile dysfunction, mild, mild to moderate, moderate and severe erectile dysfunction. Changes in the classifications will be compared between arms at 1, 3, and 6 months post-treatment.	3 and 6 months
Adverse Event Rates	Adverse Events including bruising and pain.	1, 3 and 6 months
Change in Erection Hardness Score at 1, 3, and 6 months	Change in Erection Hardness Score The Erection Hardness score is another tool to evaluate erectile function and firmness. It is scored as follows: 0-Penis does not enlarge; Penis is larger, but not hard; Penis is hard, but not hard enough for penetration; Penis is hard enough for penetration, but not completely hard; Penis is completely hard and fully rigid A higher score indicates a higher degree of erectile rigidity.	1, 3, and 6 months

Collaborators and Investigators

• Sponsor: University of Virginia

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2020
• Primary Completion (Anticipated): March 7, 2023
• Study Completion (Anticipated): March 7, 2023

Study Registration Dates

• First Submitted: June 12, 2020
• First Submitted That Met QC Criteria: June 15, 2020
• First Posted (Actual): June 16, 2020

Study Record Updates

• Last Update Posted (Actual): September 23, 2022
• Last Update Submitted That Met QC Criteria: September 22, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Sexual Dysfunctions, Psychological; Sexual Dysfunction, Physiological; Erectile Dysfunction
• Other Study ID Numbers: IRB-HSR# 190082

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No